Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD9592 |
| Synonyms | |
| Therapy Description |
AZD9592 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and MET conjugated to a topoisomerase 1 inhibitor, which potentially leads to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5737, Cancer Res (2023) 83 (7_Supplement): 5736). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD9592 | AZD 9592|AZD-9592 | EGFR Antibody 72 MET Antibody 37 | AZD9592 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and MET conjugated to a topoisomerase 1 inhibitor, which potentially leads to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5737, Cancer Res (2023) 83 (7_Supplement): 5736). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05647122 | Phase I | AZD9592 + Bevacizumab + Fluorouracil + Leucovorin AZD9592 AZD9592 + Osimertinib | First in Human Study of AZD9592 in Solid Tumors (EGRET) | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 5 |
CKB BOOST